优化全科医疗中无症状男性PSA检测以早期发现前列腺癌:英国临床共识报告
英国前列腺癌协会采用RAND/UCLA共识法,由15名专家小组对94条陈述进行两轮评分,并有7名有亲身经历男性参与部分评分。最终48/85条(56%)达成共识:不推荐筛查,但对风险高于平均的无症状男性应主动讨论PSA检测;PSA转诊最佳阈值和复检间隔等仍存不确定性。
要点
- 不推荐对无症状男性进行前列腺癌筛查。
- 对风险高于平均的无症状男性,应主动发起PSA检测讨论。
- PSA转诊最佳阈值和复检间隔仍存不确定性,需修订指南。
核心结论
- 不推荐筛查的前提下,对风险高于平均的无症状男性采取主动方式讨论PSA检测已达成共识。
- 前列腺癌诊断路径的改进可能减少了一些PSA检测相关危害,但筛查相关多个领域仍存不确定性。
研究设计与样本
- 英国前列腺癌协会推动的RAND/UCLA共识法,由15名前列腺癌专家组成的小组对涵盖五个主题的陈述进行两轮评分。
- 另有7名有亲身经历的男性组成的小组对部分陈述评分,结果反馈给主专家组。
主要发现
- 专家小组初始评审94条陈述,最终48/85条(56%)达成共识。
- 在不推荐筛查的背景下,对风险高于平均的无症状男性主动发起PSA检测讨论达成共识。
关键数值与推荐
- 共识建议对风险高于平均的无症状男性采取主动方式讨论PSA检测。
- PSA转诊最佳阈值和复检间隔仍存不确定性,未达成共识。
临床怎么用
- 全科医生对风险高于平均的无症状男性应主动发起PSA检测讨论,而非等待患者提出请求。
- 讨论内容应包括PSA检测的潜在危害和获益,并说明筛查相关不确定性。
局限性
- 共识过程未涉及筛查推荐,PSA转诊最佳阈值和复检间隔等关键问题仍存不确定性。
- 原文未报告共识小组的地域代表性及陈述未达成共识的具体原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Screening is not recommended for prostate cancer in the UK. Asymptomatic men aged ≥50 years can request a prostate-specific antigen (PSA) test following counselling on potential harms and benefits. There are areas of clinical uncertainty among GPs, resulting in the content and quality of counselling varying. AIM: To produce a consensus that can influence guidelines for UK primary care on the optimal use of the PSA test in asymptomatic men for early prostate cancer detection. DESIGN AND SETTING: Prostate Cancer UK facilitated a RAND/UCLA consensus. METHOD: Statements covering five topics were developed with a subgroup of experts. A panel of 15 experts in prostate cancer scored (round one) statements on a scale of one (strongly disagree) to nine (strongly agree). Panellists met to discuss statements before rescoring (round two). A lived experience panel of seven men scored a subset of statements with outcomes fed into the main panel. RESULTS: Of the initial 94 statements reviewed by the expert panel, a final 48/85 (56%) achieved consensus. In the absence of screening, there was consensus on proactive approaches to initiate discussions about the PSA test with men who were at higher-than-average risk. CONCLUSION: Improvements in the prostate cancer diagnostic pathway may have reduced some of the harms associated with PSA testing; however, several areas of uncertainty remain in relation to screening, including optimal PSA thresholds for referral and intervals for retesting. There is consensus on proactive approaches to testing in higher-than-average risk groups. This should prompt a review of current guidelines.
引用
- Harding TA, Martin RM, Merriel SW, et al. Optimising the use of the prostate- specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus. Br J Gen Pract. 2024. PMID: 39038964. doi:10.3399/BJGP.2023.0586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。